LogoFormulary
Compare Two Drugs
Mayo Clinic
Cleveland Clinic
Johns Hopkins Medicine
Mass General Brigham
UCSF Health
NYU Langone Health
Vanderbilt Health
Penn Medicine
Stanford Health Care
Cedars-Sinai
ASHP
Express Scripts
Updated Feb 27, 2026 · 847 new evidence links

The answer to the
question you actually
have at 2 a.m.

Drug monographs, interaction matrices, and dosing protocols — cited to FDA, ASHP, and PubMed. Built for clinicians who can't afford to guess.

Compare Two Drugs NoworBrowse 24,000 monographs →
24,000+
Drug Monographs
1M+
Evidence Links
2,400+
Institutions
Evidence database live
Last sync: 14 minutes ago
Scroll
01 / Why Formulary

Three problems every clinical pharmacist knows by name.

Hover each card to see exactly how Formulary solves it.

The 2 a.m. Problem

Your reference is three versions behind the FDA update.

Lexicomp and Micromedex monographs lag 6–18 months behind new safety communications and boxed warning revisions.

$42B
annual global cost of medication errors (WHO)
Hover to solve
Formulary Solution

Formulary syncs within 72 hours of every FDA communication.

Every monograph carries a visible "last reviewed" timestamp and a changelog. You know exactly how current your data is.

  • FDA MedWatch auto-sync
  • Boxed warning alerts
  • Full audit trail
The Polypharmacy Problem

Eight drugs. Forty-two potential interactions. One night shift.

Complex patients on multiple agents require cross-referencing every pair — a task that takes 40+ minutes with fragmented tools.

100+
new FDA-approved drugs annually
Hover to solve
Formulary Solution

Run a full 8-drug interaction matrix in under 90 seconds.

Enter any combination of drugs and Formulary returns a ranked matrix sorted by severity, mechanism, and clinical significance.

  • Severity ranking (major/moderate/minor)
  • Mechanism explanations
  • Management recommendations
The Formulary Committee Problem

P&T decisions made on PDFs from 2021.

Pharmacy directors need current comparative efficacy, biosimilar substitution laws by state, and national guideline alignment — rarely in one place.

298M
PBM-covered lives affected by formulary decisions
Hover to solve
Formulary Solution

Drug class reviews aligned to ASHP, ACC/AHA, and IDSA guidelines.

Every Formulary drug class review maps efficacy data to current guidelines, with biosimilar substitution status for all 50 states.

  • Biosimilar substitution laws by state
  • ASHP/AHFS DI integration
  • P&T committee export templates
02 / Live Comparison

Atorvastatin vs. Rosuvastatin

A complex patient: eGFR 28, on cyclosporine post-transplant, needs high-intensity statin therapy.

Run Your Own Comparison

Atorvastatin

Lipitor · HMG-CoA Reductase Inhibitor
37–51%
LDL reduction
Half-Life
14 hrs
Metabolism
CYP3A4
IndicationDoseNotes
Primary hyperlipidemia10–80 mg once dailyStart 10–20 mg
CV risk reduction (ACS)80 mg once dailyHigh-intensity
Renal impairmentNo adjustment neededHepatic metabolism

Rosuvastatin

Crestor · HMG-CoA Reductase Inhibitor
45–55%
LDL reduction
Half-Life
19 hrs
Metabolism
CYP2C9 (minor)
IndicationDoseNotes
Primary hyperlipidemia5–40 mg once dailyStart 5–10 mg
CV risk reduction (ACS)20–40 mg once dailyHigh-intensity
Renal impairment (eGFR <30)Max 10 mg/dayRenal excretion 90%
Clinical Recommendation for this case

For a post-transplant patient on cyclosporine with eGFR 28, rosuvastatin is preferred — but dose must be capped at 5 mg/day due to OATP1B1 inhibition. Atorvastatin carries higher myopathy risk with cyclosporine and requires more frequent monitoring. Renal dosing adjustment required for rosuvastatin (eGFR <30).

Cited: ACC/AHA 2018 · KDIGO 2023 · Cyclosporine PIView full citations →
03 / Evidence & Trust

Every answer traceable to peer-reviewed evidence, FDA labeling, or consensus guidelines — never just "according to our database."

FDAASHPNEJMJAMAPubMedCDCNIHACC/AHAIDSAASHP
Evidence Depth

Over 1 million citations. Every claim traceable to its source.

FDA, CDC, NIH, JAMA, NEJM, PubMed — every data point in Formulary links directly to the primary literature. No black boxes.

1M+
Evidence links
Update Frequency

Synced within 72 hrs of FDA communications

72hrMax lag from FDA
Drug Coverage

24,000+ monographs including biosimilars

24K+Drug monographs
Biosimilars

Substitution laws for all 50 states, updated quarterly

50States covered
Clinical Calculators

700+ validated calculators: CrCl, Cockcroft-Gault, weight-based dosing, renal adjustment

700+Clinical calculators
ASHP Aligned

Monographs follow AHFS DI structure — the reference required by pharmacies in most U.S. states.

U.S. Congress recognized authority
04 / Switch

See how Formulary replaces your current reference.

Select your current tool and see exactly where Formulary goes further — then run one free comparison to feel the difference yourself.

Search filters across 11 categories — but no free trial, no interaction matrix preview, $1,200+/year per seat.

Faster updates
72-hr FDA sync vs. 6–18 month lag
Free comparison
Run one full comparison before signup
Biosimilar laws
All 50 states, updated quarterly
Audit trails
Full changelog on every monograph
Run One Free Comparison

No credit card · No signup · Full citation depth

Time to answer: warfarin + fluconazole interaction
Formulary8 sec
Micromedex65 sec
Lexicomp48 sec

Internal usability study, n=42 clinical pharmacists, Feb 2026

Feature coverage
FeatureFormularyMicromedexLexicomp
72-hr FDA sync
Free comparison trial
Biosimilar laws (all 50 states)
Interaction matrix (8+ drugs)
ASHP/AHFS DI aligned
Changelog per monograph